AstraZeneca plc Company Profile (LON:AZN)

About AstraZeneca plc (LON:AZN)

AstraZeneca plc logoAstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: LON:AZN
  • CUSIP: N/A
  • Web:
  • Market Cap: £54.75 billion
  • Outstanding Shares: 1,266,000,000
Average Prices:
  • 50 Day Moving Avg: GBX 5,187.89
  • 200 Day Moving Avg: GBX 4,861.95
  • 52 Week Range: GBX 3,996 - GBX 5,520
  • Trailing P/E Ratio: 16.20
  • P/E Growth: 3.29
Sales & Book Value:
  • Annual Revenue: £22.29 billion
  • Price / Sales: 2.46
  • Book Value: GBX 10.26 per share
  • Price / Book: 4.22
  • Dividend Yield: 4.3%
  • EBIDTA: £5.84 billion
  • Net Margins: 9.47%
  • Return on Equity: 15.47%
  • Return on Assets: 3.33%
  • Average Volume: 2.15 million shs.
Frequently Asked Questions for AstraZeneca plc (LON:AZN)

What is AstraZeneca plc's stock symbol?

AstraZeneca plc trades on the London Stock Exchange (LON) under the ticker symbol "AZN."

How often does AstraZeneca plc pay dividends? What is the dividend yield for AstraZeneca plc?

AstraZeneca plc declared a dividend on Thursday, July 27th. Shareholders of record on Thursday, August 10th will be paid a dividend of GBX 68.90 per share on Monday, September 11th. This represents a dividend yield of 1.35%. The ex-dividend date is Thursday, August 10th. The official announcement can be seen at this link. View AstraZeneca plc's Dividend History.

Where is AstraZeneca plc's stock going? Where will AstraZeneca plc's stock price be in 2017?

20 brokers have issued 12-month price objectives for AstraZeneca plc's stock. Their predictions range from GBX 3,900 to GBX 6,500. On average, they expect AstraZeneca plc's stock price to reach GBX 5,241.37 in the next year. View Analyst Ratings for AstraZeneca plc.

Who are some of AstraZeneca plc's key competitors?

Who are AstraZeneca plc's key executives?

AstraZeneca plc's management team includes the folowing people:

  • Pascal Soriot, Executive Director and Chief Executive Officer
  • Marc Dunoyer, Executive Director, Chief Financial Officer
  • Fiona Cicconi, Executive Vice-President, Human Resources
  • Sean Bohen M.D., Ph.D., Chief Medical Officer, Executive Vice President - Global Medicines Development
  • Pam P. Cheng, Executive Vice President - Operations and Information Technology
  • Ruud Dobber, Executive Vice President, North America
  • Bahija Jallal Ph.D., Executive Vice President, MedImmune
  • Mark Mallon, Executive Vice President, Global Product and Portfolio Strategy, Global Medical Affairs & Corporate Affairs Executive Vice-President, International West
  • Menelas Pangalos, Executive Vice President - IMED Biotech Unit and Global Business Development
  • Leon Wang, Executive Vice President - Asia Pacific

How do I buy AstraZeneca plc stock?

Shares of AstraZeneca plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is AstraZeneca plc's stock price today?

One share of AstraZeneca plc stock can currently be purchased for approximately GBX 4,325.

MarketBeat Community Rating for AstraZeneca plc (LON AZN)
Community Ranking:  2.1 out of 5 ( )
Outperform Votes:  820 (Vote Outperform)
Underperform Votes:  1,163 (Vote Underperform)
Total Votes:  1,983
MarketBeat's community ratings are surveys of what our community members think about AstraZeneca plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for AstraZeneca plc (LON:AZN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 9 Hold Ratings, 9 Buy Ratings
Consensus Rating:Hold (Score: 2.35)
Consensus Price Target: GBX 5,241.37

Analysts' Ratings History for AstraZeneca plc (LON:AZN)
DateFirmActionRatingPrice TargetDetails
7/28/2017Credit Suisse GroupLower Price TargetNeutralGBX 5,000 -> GBX 4,700View Rating Details
7/28/2017Deutsche Bank AGReiterated RatingBuyGBX 5,700View Rating Details
7/27/2017S&P GlobalSet Price TargetNeutralGBX 4,500View Rating Details
7/27/2017Shore CapitalReiterated RatingHoldView Rating Details
7/27/2017Liberum CapitalReiterated RatingBuyGBX 5,500View Rating Details
7/26/2017Barclays PLCReiterated RatingOverweightGBX 6,300View Rating Details
7/21/2017J P Morgan Chase & CoReiterated RatingNeutralView Rating Details
7/21/2017BNP ParibasReiterated RatingNeutralView Rating Details
7/14/2017Goldman Sachs Group, Inc. (The)Reiterated RatingSellGBX 3,900View Rating Details
7/13/2017Kepler Capital MarketsReiterated RatingBuyGBX 5,500View Rating Details
7/13/2017Citigroup Inc.Reiterated RatingBuyGBX 6,000View Rating Details
7/12/2017Jefferies Group LLCLower Price TargetHoldGBX 5,500 -> GBX 5,300View Rating Details
7/4/2017HSBC Holdings plcDowngradeReduceGBX 4,500View Rating Details
6/23/2017Morgan StanleyReiterated RatingOverweightGBX 5,600View Rating Details
5/26/2017InvestecBoost Price TargetHoldGBX 4,600 -> GBX 5,000View Rating Details
5/17/2017Berenberg BankBoost Price TargetBuyGBX 5,670 -> GBX 5,850View Rating Details
4/28/2017Sanford C. BernsteinSet Price TargetNeutralGBX 4,736View Rating Details
4/3/2017Beaufort SecuritiesReiterated RatingHoldView Rating Details
3/23/2017Societe GeneraleReiterated RatingBuyView Rating Details
2/28/2017Bryan, Garnier & CoReiterated RatingBuyGBX 5,400View Rating Details
6/24/2016Independent Research GmbHSet Price TargetSellGBX 3,650View Rating Details
5/10/2016Oddo SecuritiesReiterated RatingBuyGBX 5,400View Rating Details
5/5/2016Charles StanleyUpgradeStrong-BuyView Rating Details
3/24/2016NatixisReiterated RatingNeutralGBX 4,456View Rating Details
3/23/2016NomuraLower Price TargetHoldGBX 4,880 -> GBX 4,350View Rating Details
2/12/2016Baader BankReiterated RatingHoldGBX 4,400View Rating Details
2/9/2016AlphaValueUpgradeBuyGBX 4,640View Rating Details
2/4/2016S&P Equity ResearchSet Price TargetNeutralGBX 4,500View Rating Details
2/2/2016HandelsbankenReiterated RatingAccumulateGBX 5,220.30View Rating Details
1/28/2016Pareto SecuritiesReiterated RatingSellGBX 3,855.35View Rating Details
1/27/2016SwedbankReiterated RatingBuyGBX 5,115.47View Rating Details
1/13/2016Nordea Equity ResearchReiterated RatingHoldGBX 4,698.35View Rating Details
(Data available from 7/28/2015 forward)


Earnings History for AstraZeneca plc (LON:AZN)
No earnings announcements for this company have been tracked by


Earnings Estimates for AstraZeneca plc (LON:AZN)
Current Year EPS Consensus Estimate: $3.69 EPS


Dividend History by Quarter for AstraZeneca plc (LON AZN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/27/2017GBX 68.901.35%8/10/20178/10/20179/11/2017
2/2/2017GBX 150.203.52%2/16/20172/16/20173/20/2017
7/28/2016GBX 68.701.37%8/11/20168/11/20169/12/2016
2/4/2016GBX 1313.16%2/18/20162/18/20163/21/2016
7/30/2015GBX 57.501.33%8/13/20158/13/20159/14/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for AstraZeneca plc (LON:AZN)
Insider Trades by Quarter for AstraZeneca plc (LON:AZN)
Insider Trades by Quarter for AstraZeneca plc (LON:AZN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/27/2015Courtois,Jean-PhilippeInsiderBuy900GBX 4,423£39,807
8/28/2015Soriot,PascalInsiderBuy76,300GBX 3,960£3,021,480
5/7/2015Marc DunoyerInsiderBuy10,000GBX 4,397£439,700
4/30/2015Ann CairnsInsiderBuy1,100GBX 4,455£49,005
4/29/2015Shriti VaderaInsiderBuy3,500GBX 4,563£159,705
4/28/2015Graham ChipchaseInsiderBuy1,100GBX 4,606£50,666
4/27/2015Bruce BurlingtonInsiderBuy600GBX 4,662£27,972
(Data available from 1/1/2013 forward)


Headline Trends for AstraZeneca plc (LON:AZN)
Latest Headlines for AstraZeneca plc (LON:AZN)
DateHeadline logoAstraZeneca Plc's (AZN) CEO Pascal Soriot on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha - July 27 at 9:47 PM logo[$$] AstraZeneca Shocker Reminds Investors Miracle Drugs Are No Remedy for Risk - July 27 at 9:47 PM logo[$$] AstraZeneca Faces Major Setback Over Cancer Drugs - July 27 at 9:47 PM logoMighty AstraZeneca Takes a Lickin' on Failed Mystic Trial - July 27 at 9:47 PM logoAstraZeneca plc (AZN) Given a GBX 4,500 Price Target by S&P Global Analysts - July 27 at 4:05 PM logoAstraZeneca plc (ADR) (AZN) Stock Tanks on Lung Cancer Drug Disappointment - July 27 at 12:10 PM logoAstraZeneca plc to Issue Dividend of GBX 68.90 (AZN) - July 27 at 11:16 AM logoWhy Is AstraZeneca Sinking Today? - July 27 at 10:20 AM logoAstraZeneca plc (AZN) Given a GBX 5,150 Price Target at UBS AG - July 27 at 6:20 AM logoIs Lower Revenue in the Cards for AstraZeneca’s 2Q17? - July 26 at 9:59 PM logoAstraZeneca Receives EU Approval For Faslodex Breast Cancer Drug - July 26 at 4:57 PM logoAstraZeneca plc (AZN) Rating Reiterated by J P Morgan Chase & Co - July 22 at 12:18 PM logoAstraZeneca plc (LON:AZN) Receives "Neutral" Rating from BNP Paribas - July 21 at 8:16 AM logoAstraZeneca plc (AZN) Receives Average Rating of "Hold" from Analysts - July 21 at 7:36 AM logoChaos At AstraZeneca - Seeking Alpha - July 19 at 10:33 PM logoAstraZeneca plc (LON:AZN) to Release Earnings on Wednesday - July 19 at 2:58 AM logoAstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise - Nasdaq - July 17 at 9:39 PM logoAstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise - July 17 at 9:38 PM logoCEO departures not always bad for companies: Cramer - July 17 at 9:38 PM logoAstraZeneca Shares Slump On Reports Teva Courting CEO Pascal Soriot - - July 14 at 11:13 PM logoPotential AstraZeneca C-Suite Shuffle Rekindles Takeover Chatter - - July 14 at 6:11 PM logoGoldman Sachs Group, Inc. (The) Reiterates GBX 3,900 Price Target for AstraZeneca plc (AZN) - July 14 at 11:37 AM logoBUZZ-US STOCKS ON THE MOVE-Yandex, AstraZeneca, Target, Teva, Delta Air Lines - Nasdaq - July 13 at 10:18 PM logo[$$] Mystery at AstraZeneca: Is CEO Pascal Soriot Staying or Going? - July 13 at 10:18 PM logoAnalyst Wonders If AstraZeneca's CEO Would Be A Fit At Teva - July 13 at 5:28 PM logoMystery at AstraZeneca: Is CEO Pascal Soriot Staying or Going? - July 13 at 5:13 PM logoAstraZeneca is Oversold - Nasdaq - July 13 at 5:13 PM logoIs Parting Such Sweet Soriot For AstraZeneca? - Seeking Alpha - July 13 at 5:13 PM logoAstraZeneca plc (AZN) Earns "Hold" Rating from Shore Capital - July 13 at 3:06 PM logoAstraZeneca plc's (LON:AZN) Neutral Rating Reaffirmed at J P Morgan Chase & Co - July 13 at 6:58 AM logoLondon Markets: FTSE 100 slips as AstraZeneca slides - July 13 at 5:16 AM logoPerformance of AstraZeneca Stock in 2Q17 - July 10 at 4:22 PM logoAstraZeneca plc (LON:AZN) Stock Rating Reaffirmed by Citigroup Inc. - July 9 at 9:40 PM logoBarclays PLC Boosts AstraZeneca plc (AZN) Price Target to GBX 6,300 - July 3 at 1:33 PM logoAstraZeneca plc (AZN) Receives "Buy" Rating from Deutsche Bank AG - July 1 at 10:34 PM logoAnalyst Recommendations for AstraZeneca in June 2017 - June 30 at 9:27 PM logoCanada's top court hands patent win to pharmaceutical companies - Nasdaq - June 30 at 4:22 PM logoAstraZeneca plc (AZN) Given Consensus Recommendation of "Hold" by Analysts - June 26 at 7:44 AM logoAstraZeneca plc (AZN) Rating Reiterated by Morgan Stanley - June 23 at 7:14 AM logo[$$] Repare Therapeutics Grabs $68 Million, Targets 'Synthetic Lethality' in Cancer - June 22 at 8:56 PM logoAstraZeneca plc (AZN) Receives Neutral Rating from Credit Suisse Group - June 19 at 11:52 PM logoAstraZeneca plc (AZN) Given Hold Rating at Shore Capital - June 17 at 10:58 PM logoJefferies Group LLC Boosts AstraZeneca plc (AZN) Price Target to GBX 5,500 - June 17 at 1:38 PM logoAstraZeneca plc (AZN) Given Buy Rating at Deutsche Bank AG - June 17 at 1:02 PM logoAstraZeneca Presents New Data On Farxiga - June 12 at 4:48 PM logoDecember 15th Options Now Available For AstraZeneca (AZN) - June 12 at 4:48 PM logoWhen to Roll Over - June 12 at 4:48 PM logoMorgan Stanley Reiterates "Buy" Rating for AstraZeneca plc (AZN) - June 11 at 2:02 PM logoAstraZeneca plc (AZN) Receives Hold Rating from Shore Capital - June 8 at 11:02 PM logoAstraZeneca (AZN) Divests Migraine Drug Rights Beyond Japan - Nasdaq - June 8 at 9:32 PM


Social activity is not available for this stock.


AstraZeneca plc (AZN) Chart for Friday, July, 28, 2017

This page was last updated on 7/28/2017 by Staff